From a cellular pharmacy viewpoint, Relafen 750 (naproxen sodium) signifies a compelling case study in noncopyrightal anti-inflammatory medication action. Its mode of reducing inflammation and discomfort copyrights primarily on the inhibition of cyclooxygenase (COX) enzymes , specifically COX-1 and COX-2. Understanding the selective aspects of this